Publication | Closed Access

Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial

Second-line TreatmentOncologyMalignant Pleural MesotheliomaPleural DiseasePharmacotherapyCancer TreatmentMedicineRadiation Oncology